Fewer than one in seven advanced cancer patients qualifies for a precision medicine today. Darrin Miles took $125 million and a quiet pun for a company name and went looking for the other six.
Nested Therapeutics is named for a hunch. The mutations worth drugging are nested - tucked inside high-conviction cancer targets, in pockets the rest of the industry walks past because they look impossible to reach. Darrin Miles runs the company built to pry them open, out of a lab on Massachusetts Avenue in Cambridge with a headcount you could seat at three dinner tables.
He is, by training, an economist. The degree on the wall reads applied economics, Cornell - not chemistry, not biology, not the usual entry ticket for the corner office of a drug-discovery startup. What Miles brought instead was twenty years of watching cancer drugs cross the last mile from a promising molecule to a prescription a doctor actually writes. He has seen which ones make it and which ones stall, and he has opinions about why.
That perspective is the bet. Nested is stacked with computational biophysicists, structural biologists and machine-learning people chasing cryptic binding pockets. Miles is the one asking who, in the end, gets the medicine - and whether the answer is a wide enough door to be worth the decade it takes to walk through it.
Patients deserve more and better options, and our approach holds the promise to make first- and best-in-class precision oncology treatments available to a larger addressable population.- Darrin Miles, on Nested's launch
Here is the uncomfortable arithmetic Nested keeps repeating: fewer than 1% of cancer-associated mutations have an FDA-approved medicine pointed at them. Precision oncology, the field that promised to match a drug to a tumor's exact genetic fingerprint, currently helps fewer than one advanced cancer patient in seven. The science is real. The reach is narrow.
Nested's answer runs in three moves. First, map the clusters of mutations onto the three-dimensional shape of the proteins they corrupt. Second, find the druggable pockets and the mechanisms that actually drive the cancer. Third, design a molecule built for that specific pocket. The lead program, NEST-1, aims at multiple components of the MAPK pathway - a circuit that goes haywire in a long list of tumors.
It is an engineering pitch as much as a biology one: genomics, computational biophysics, machine learning and chemical biology pointed at targets the field had filed under undruggable. Miles's job is to keep that machine fed, funded and aimed at problems big enough to matter.
Cluster cancer mutations onto the structural proteome to see where the damage really lives.
Identify druggable pockets and the mechanisms driving the cancer - including the cryptic ones.
Engineer a novel small molecule optimized for that exact pocket. First program: NEST-1, MAPK pathway.
Before he was anyone's CEO, Miles spent fourteen years at Genentech - one of the handful of companies that effectively wrote the rulebook for modern biotech. He moved through global program leadership, marketing, sales management and market access, and his fingerprints touched names oncology clinicians say without thinking: Herceptin, Tarceva, Perjeta, Rituxan. These were not science projects. They were the drugs that proved targeted therapy could be a business.
Then came Agios Pharmaceuticals, where Miles rose to Chief Commercial Officer over oncology and rare disease. He ran the precision oncology program management function through the development and approval of IDHIFA and TIBSOVO - the first therapies for mutant-IDH acute myeloid leukemia, a cancer that had gone a long time without good news. He had now done the hardest thing in the industry twice: turn biology into an approved, prescribed, paid-for medicine.
In 2022, Versant Ventures handed him a clean sheet. Nested launched in October that year with $125 million in the bank, a $90 million Series A led by the life-sciences team at Goldman Sachs Asset Management, and a roster of investors - Foresite, Avidity, Cowen Healthcare, Section 32 - that does not write checks for vague ambitions.
Running a discovery startup means convincing scientists with their pick of jobs to bet years on yours. Nested's bench reads like a who's-who of the chemistry-meets-cancer world - the people Miles helped pull into the same building.